MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

32.19 -4.05

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

31.98

Max

32.47

Belangrijke statistieken

By Trading Economics

Inkomsten

-14M

-81M

Verkoop

75K

75K

EPS

-1.22

Winstmarge

-108,422.667

Werknemers

198

EBITDA

-7.8M

-81M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+62.11% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

472M

2.1B

Vorige openingsprijs

36.24

Vorige sluitingsprijs

32.19

Nieuwssentiment

By Acuity

100%

0%

333 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 apr 2026, 17:04 UTC

Belangrijke Marktbewegers

FDA Rejects Replimune's Melanoma Drug for a Second Time

11 apr 2026, 00:00 UTC

Winsten
Acquisities, Fusies, Overnames

Big Yachts, Big Bucks -- Barrons.com

10 apr 2026, 21:55 UTC

Acquisities, Fusies, Overnames

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 apr 2026, 21:01 UTC

Winsten

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

10 apr 2026, 20:50 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

10 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

10 apr 2026, 20:31 UTC

Marktinformatie

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 apr 2026, 20:10 UTC

Acquisities, Fusies, Overnames

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 apr 2026, 19:15 UTC

Marktinformatie

Global Energy Roundup: Market Talk

10 apr 2026, 19:15 UTC

Marktinformatie

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 apr 2026, 19:08 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

10 apr 2026, 19:08 UTC

Marktinformatie

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 apr 2026, 18:38 UTC

Marktinformatie

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10 apr 2026, 18:25 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Precious Metals Finish With Weekly Gains -- Market Talk

10 apr 2026, 18:05 UTC

Marktinformatie

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10 apr 2026, 17:31 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10 apr 2026, 17:26 UTC

Winsten

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10 apr 2026, 17:10 UTC

Marktinformatie

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10 apr 2026, 17:00 UTC

Belangrijke Nieuwsgebeurtenissen

Construction Business Taking a Hit From Iran Conflict -- WSJ

10 apr 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

10 apr 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

10 apr 2026, 16:12 UTC

Winsten

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10 apr 2026, 16:11 UTC

Winsten

Partners Group: Traditional Programs Contributed $3.3B

10 apr 2026, 16:10 UTC

Winsten

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10 apr 2026, 16:10 UTC

Winsten

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10 apr 2026, 16:10 UTC

Winsten

Partners Group 1Q New Client Demand $8.3B

10 apr 2026, 16:09 UTC

Winsten

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10 apr 2026, 15:54 UTC

Acquisities, Fusies, Overnames

Plenitude Completes Acquisition of Acea Energia

10 apr 2026, 15:38 UTC

Marktinformatie

Global Energy Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

62.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 54.5 USD  62.11%

Hoogste 90 USD

Laagste 24 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

9

Buy

1

Hold

1

Sell

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat